HIGH POINT CLINICAL TRIALS CENTER ANNOUNCES THE PRESENTATION OF THREE POSTERS AT THE AMERICAN COLLEGE OF CLINICAL PHARMACOLOGY MEETING IN BETHESDA, MD - High Point Clinical Trials Center
 

HIGH POINT CLINICAL TRIALS CENTER ANNOUNCES THE PRESENTATION OF THREE POSTERS AT THE AMERICAN COLLEGE OF CLINICAL PHARMACOLOGY MEETING IN BETHESDA, MD

High Point, North Carolina (July 23rd 2018) – High Point Clinical Trial Center (HPCTC), North Carolina’s premier clinical research facility conducting complex clinical pharmacology testing in Healthy Participants and a wide range of Patient populations  is proud to announce the approval of three posters for the 2018 annual American College of Clinical Pharmacology meeting.

 

“The acceptance of our cutting-edge research abstracts at the ACCP conference range from novel drug development clinical pharmacology results to innovative methodology and testing regimens for efficient identification of NASH/NAFLD patients and demonstrates HPCTC’s commitment to “Science Driving Service.” said Dr. Lorraine Rusch, President.

 

“This research represents the best in class collaboration between biopharma scientist-clients and our staff physicians and clinical pharmacologists and I am delighted that our research facility leads the industry in research which directly translates into novel pharmaceutical products and new methodologies for earlier detection of the emerging metabolic epidemics of NAFLD (Nonalcoholic fatty liver disease) and NASH (Nonalcoholic steatohepatitis) added Dr. Rusch.

 

The Poster details are as follows:

  • Compstatin Cp40 (AMY-101): a C3-targeted complement inhibitor reaching its prime for bedside intervention
    1. Date: September 23rd and 24th 2018
    2. Presenter: Lorraine Rusch, PhD

 

  • Comparing FibroScan results between african-american and caucasian populations when pre-screening for NAFLD/NASH research studies
    1. Date: September 24th and 25th 2018
    2. Presenter: Clayton Dehn, MS

 

  • Hyperuricemia May be a Suitable Cost-Containing Screening Gateway for Determining NAFLD/NASH Clinical Trial Eligibility Requiring Hepatic Steatosis and/or Fibrosis
    1. Date: September 24th and 25th 2018
    2. Presenter: Clayton Dehn, MS

 

For more information, visit highpointctc.com or https://www.accp1.org/

 

About High Point Clinical Trials Center (HPCTC)

HPCTC was “born from biotech” in 2008 as an internal clinical research unit for TransTech Pharma (now vTv Therapeutics), a drug discovery and development company. As the largest commercial clinical research unit in North Carolina, HPCTC conducts First-in-Human, clinical Proof-of-Concept, and traditional IND/NDA-enabling clinical pharmacology phase I/II trials for Contract Research Organizations, biotechnology and pharmaceutical companies worldwide.

In addition to early development studies, HPCTC conducts studies across a range of therapeutic areas including metabolic disorders, pulmonary disease and CNS in a pleasant and comfortable environment managed by caring and experienced staff. Participant safety, protocol adherence, regulatory compliance and effective communication are the Company’s top priorities.

 

Contacts:

Doug Copeland, Executive Vice President, Corporate Development
High Point Clinical Trials Center
DCopeland@highpointctc.com
+1 336 255 2353

 

About the American College of Clinical Pharmacology

As an organization whose primary role is education, ACCP does not concentrate on any one aspect of the discipline. Rather, it seeks to address the educational needs of its diverse membership and all healthcare professionals, covering a range of topics that span the entire area of the interaction between drugs and humans. These areas include, but are not limited to, pharmaceutical chemistry, biochemistry, drug metabolism, pharmacokinetics, pharmacodynamics, pharmacometrics, pharmacogenomics clinical pharmacology practice in the outpatient and inpatient settings, human toxicology, drug interactions and clinical drug trials. The diversity of ACCP is expressed not only in the composition of its membership, but also in its leadership. Maintaining a balance of elected Regents and Officers from all pertinent professional backgrounds ensures that ACCP remains attuned to the needs of all professionals engaged in the practice of or with a strong interest in clinical pharmacology, from the research laboratory (academic and industrial) to the classroom, and from the clinical trial to improved patient care.